A Phase 2 Study Adding the Drugs Tazemetostat or Zanubrutinib to Usual Treatment for People with Large B-Cell Lymphoma that Returned or Did Not Respond to Earlier Treatment
This phase II trial compares the effect of tazemetostat or zanubrutinib in combination with the usual treatment with tafasitamab and lenalidomide versus the usual treatment alone in treating patients with large B-cell lymphoma that has returned after a period of responding to treatment (relapsed) or that has not responded to earlier treatment (refractory). This trial also aims to find whether lymphoma’s cell of origin affects how the cancer responds to study treatment. Tazemetostat is in a class of medications called EZH2 inhibitors. The EZH2 gene provides instructions for making a type of enzyme called a histone methyltransferase which is involved in gene expression and cell division. Blocking EZH2 may help keep cancer cells from growing. Zanubrutinib is in a class of medications called kinase inhibitors. It blocks a protein called Bruton's tyrosine kinase (BTK), which may help keep cancer cells from growing and spreading. Tafasitamab is a monoclonal antibody. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Tafasitamab binds to a protein called CD19, which is found on most B cells (a type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells in the bone marrow. The addition of tazemetostat or zanubrutinib to usual treatment with tafasitamab and lenalidomide may be able to shrink cancer or extend the time without cancer symptoms coming back better than the usual treatment alone in patients with relapsed or refractory large B-cell lymphoma.
Inclusion Criteria
- Participants must have: * Histologically confirmed relapsed/refractory LBCL as outlined by the World Health Organization (WHO) guidelines, classified as one of the following: * Large B-cell lymphoma, GCB and non-GCB types * Follicular lymphoma, grade 3B * Transformed lymphoma * High grade B-cell lymphoma with or without MYC, BCL2 and/or BCL6 rearrangements
- Participants must have staging imaging performed within 28 days prior to registration, as follows. Positron emission tomography (PET)-computed tomography (CT) baseline scans are strongly preferred; diagnostic quality magnetic resonance imaging (MRI), contrast-enhanced CT, or contrast-enhanced MRI scans are also acceptable if PET-CT is not feasible at baseline. * NOTE: PET-CT will be required at end of treatment (EOT) and progression for response assessment. All measurable lesions (longest diameter >= 1.5 cm) must be assessed within 28 days prior to registration. Tests to assess non-measurable disease must be performed within 28 days prior to registration. All disease must be documented on the Baseline Tumor Assessment Form.
- Participants must not have active lymphomatous involvement of the central nervous system (CNS) because the treatments used in this study are not effective to sufficiently penetrate the blood brain barrier.
- Participants must not have known Richter’s transformation (transformation from chronic lymphocytic leukemia [CLL] or small lymphocytic lymphoma [SLL])
- Participants must not have known abnormalities associated with myelodysplastic syndrome (MDS) (e.g., del 5q, chr 7 abn) and myeloproliferative neoplasms (MPN) (e.g., JAK2 V617F) observed in cytogenetic testing and deoxyribonucleic acid (DNA) sequencing. Testing is not required for eligibility determination.
- Participants must not have a known prior history of T-cell lymphoblastic lymphoma (T-LBL)/T-cell acute leukemia (T-ALL) or B-cell acute lymphoblastic leukemia (B-ALL). Testing is not required for eligibility determination.
- Participants must have cell of origin (COO) determination of germinal center (GC)(GCB or non GCB) of LBCL based on Hans immunohistochemistry algorithm (CD10, BCL6, MUM1) as noted on pathology report.
- Participants must not be a candidate based on investigator assessment to receive autologous stem cell transplant (ASCT) or must have declined ASCT. Participants who had disease progression after stem cell transplant or cellular therapy (such as chimeric antigen receptor (CAR) T-cell) are eligible.
- Participants must not have received prior treatment with tafasitamab and/or lenalidomide.
- Participants must not have had prior BTK inhibitor or tazemetostat.
- Participants must have had 1-5 prior systemic treatment regimens, including one systemic multiagent regimen for aggressive lymphoma.
- Participants who have received prior systemic therapy must have completed their last treatment prior to registration. Participants must have recovered from previous therapy.
- Steroid use for the control of non-Hodgkin lymphoma symptoms is allowable, but must be discontinued prior to Cycle 1, Day 1.
- Participants must not have any known allergy or reaction to any component of tafasitamab, lenalidomide, tazemetostat or zanubrutinib.
- Participants must not be receiving direct vitamin K inhibitors or strong or moderate CYP3A inhibitors or inducers at the date of registration. * Note: Because the list of these agents is constantly changing, it is important to regularly consult a frequently updated medical reference.
- Participant must be >= 18 years old.
- Participant must have Zubrod Performance Status of 0-3.
- Participant must have a complete medical history and physical exam within 28 days prior to registration.
- Absolute neutrophil count >= 1.0 x 10^3/uL (within 28 days prior to registration). * If there is documented lymphomatous involvement of the bone marrow as assessed by bone marrow biopsy within 90 days prior to registration, participants must have: Absolute neutrophil count (ANC) >= 0.75 x 10^3/uL.
- Platelets >= 75 x 10^3/uL (within 28 days prior to registration). * If there is documented lymphomatous involvement of the bone marrow as assessed by bone marrow biopsy within 90 days prior to registration, participants must have: Platelets >= 50 x 10^3/uL.
- Aspartate aminotransferase (AST) =< 3 x institutional upper limit of normal (IULN), alanine aminotransferase (ALT) =< 3 x IULN (within 28 days prior to registration) unless due to Gilbert’s disease, hemolysis, or lymphomatous involvement of liver. * Participants with lymphomatous involvement of the liver must have AST =< 5 x IULN, ALT =< 5 x IULN.
- Total bilirubin =< 1.5 x IULN (within 28 days prior to registration) unless due to Gilbert’s disease, hemolysis, or lymphomatous involvement of liver. * Participants with lymphomatous involvement of the liver must have total bilirubin =< 5 x IULN.
- Participants must have a calculated creatinine clearance >= 30 mL/min using the Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to registration.
- Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification within 28 days prior to registration. To be eligible for this trial, patients should be class 2B or better.
- Participants must have recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia.
- Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at randomization and have undetectable viral load test on the most recent test results obtained within 6 months prior to registration.
- Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load on the most recent test results obtained within the last year and received suppressive therapy.
- Participants with a history of hepatitis C virus (HCV) infection must have an undetectable viral load. Participants currently being treated for HCV infection must have undetectable HCV viral load test on the most recent test results obtained within 28 days prior to registration.
- Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen.
- Participants must not be pregnant or nursing and must follow the guidelines according to the lenalidomide Risk Evaluation and Mitigation Strategies (REMS) program. The effects of tazemetostat, zanubrutinib, lenalidomide and tafasitamab, and the combination of these drugs have not been studied on the developing human fetus are the effects are unknown. Individuals who are of reproductive potential must have agreed to use a highly effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of “reproductive potential”. In addition to routine contraceptive methods, “acceptable contraception” also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen. NOTE: For further information regarding pregnancy monitoring, please refer to the Lenalidomide Risk Evaluation and Mitigation Strategy (REMS).
- Participants must be able to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption, such as malabsorption syndrome or major resection of the stomach or bowels.
- Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the Southwest Oncology Group (SWOG) Specimen Tracking System.
- Participants who can complete the FACT-Lym and PRO-CTCAE forms in English or Spanish must agree to participate in the patient-reported outcome study.
- Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines. * For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and central institutional review board (CIRB) regulations.
Additional locations may be listed on ClinicalTrials.gov for NCT05890352.
Locations matching your search criteria
United States
Arizona
Tucson
California
Beverly Hills
Duarte
Huntington Beach
Lancaster
Long Beach
Los Angeles
Newport Beach
South Pasadena
Torrance
Upland
Florida
Fort Lauderdale
Miami Beach
Illinois
Chicago
Danville
Effingham
Mattoon
New Lenox
Orland Park
Shiloh
Urbana
Indiana
Crown Point
Dyer
Hobart
Indianapolis
Munster
Valparaiso
Iowa
Ankeny
Cedar Rapids
Clive
Des Moines
Michigan
Ann Arbor
Brighton
Canton
Chelsea
Flint
Lansing
Livonia
Pontiac
Ypsilanti
Minnesota
Deer River
Duluth
Hibbing
Sandstone
Virginia
Mississippi
Jackson
Missouri
Creve Coeur
Saint Louis
Saint Peters
New York
New York
Rochester
Webster
Oklahoma
Oklahoma City
Oregon
Newberg
Oregon City
Portland
South Carolina
Charleston
Texas
Houston
San Antonio
Utah
Salt Lake City
Virginia
Richmond
Wisconsin
Appleton
Ashland
Burlington
Eau Claire
Germantown
Grafton
Green Bay
Kenosha
La Crosse
Marinette
Marshfield
Milwaukee
Minocqua
Oshkosh
Racine
Rice Lake
Sheboygan
Stevens Point
Summit
Two Rivers
Wauwatosa
West Allis
Weston
PRIMARY OBJECTIVE - SAFETY RUN-IN:
I. To determine the recommended phase II dose of tafasitamab + lenalidomide + tazemetostat AND of tafasitamab + lenalidomide + zanubrutinib.
PRIMARY OBJECTIVE - RANDOMIZED PHASE II STUDY:
I. To compare progression-free survival (PFS) of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) treated with tafasitamab + lenalidomide + tazemetostat versus (vs) control (tafasitamab + lenalidomide) AND treated with tafasitamab + lenalidomide + zanubrutinib vs control. (Randomized Phase II Study)
SECONDARY OBJECTIVE - SAFETY RUN-IN:
I. To determine the recommended phase II dose of tafasitamab + lenalidomide + tazemetostat AND of tafasitamab + lenalidomide + zanubrutinib. To observe and record anti-tumor activity.
SECONDARY OBJECTIVES - RANDOMIZED PHASE II STUDY:
I. To estimate the hazard ratio for PFS for control vs. tafasitamab + lenalidomide + tazemetostat in germinal center B-cell (GCB) and non-GCB (activated B-cell [ABC]/unclassified) subsets.
II. To estimate the hazard ratio for PFS for control vs. tafasitamab + lenalidomide + zanubrutinib in GCB and non-GCB (ABC/unclassified) subsets.
III. To estimate progression-free survival (PFS), overall response rate (ORR), complete response rate (CR), partial response rate (PR), duration of response (DOR), event-free survival (EFS), overall survival (OS), in GCB and non-GCB LBCL for each treatment.
IV. To evaluate adverse events within each treatment arm.
OTHER OBJECTIVES:
I. To explore PFS within subgroups defined by molecular profile (e.g., MCD, BN2, N1 and EZB) and genetic subtypes.
II. To explore PFS in the tafasitamab-lenalidomide control arm vs that in matched historical control from L-MIND and realMIND studies.
III. To assess frailty (Cumulative Illness Rating Scale [CIRS] and Timed Get Up and Go [TUG]) and its correlation with outcome.
PRIMARY PATIENT-REPORTED OUTCOMES OBJECTIVE:
I. To compare patient-reported lymphoma-specific symptoms as measured by the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Trial Outcome Index sub-scale at 3 months after randomization between the control arm and each experimental arm (Arm 1 versus Arm 2 and Arm 3 versus Arm 2).
EXPLORATORY PATIENT-REPORTED OUTCOMES OBJECTIVES:
I. To compare patient-reported quality of life using the FACT-General (G) subscale score and the FACT-Lym total score at 3 months after randomization between the control arm and each experimental arm.
II. To compare quality of life over time between treatment arms from baseline to 12 months after randomization as measured by the FACT-Lym trial outcome index (TOI), FACT-G, and FACT-Lym total score using longitudinal analysis.
III. To compare participant-reported toxicity (treatment side effect) symptoms using selected Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE) items between experimental vs control arms.
BANKING OBJECTIVE:
I. To bank specimens for future correlative studies.
OUTLINE: This is a safety run-in dose-escalation study of tazemetostat and zanubrutinib in combination with fixed dose tafasitamab and lenalidomide followed by a randomized phase II trial.
PART I (SAFETY RUN-IN): Patients are assigned to 1 of 2 arms (Arms I or III) per treating investigator’s choice.
ARM I: Patients receive tafasitamab intravenously (IV) on cycle 1 days 1, 4, 8, 15 and 22, cycles 2-3 days 1, 8, 15 and 22, cycles 4-13 days 1 and 15, lenalidomide orally (PO) once daily (QD) cycles 1-13 days 1-21, and tazemetostat PO twice daily (BID) cycles 1-13 days 1-28 during the study. Patients also undergo positron emission tomography/computed tomography (PET/CT) and CT or magnetic resonance imaging (MRI) scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and while on the study and may undergo tissue and/or bone marrow biopsy at screening, on study, and at time of progression.
ARM III: Patients receive tafasitamab IV on cycle 1 days 1, 4, 8, 15 and 22, cycles 2-3 days 1, 8, 15 and 22, cycles 4-13 days 1 and 15, lenalidomide PO QD cycles 1-13 days 1-21, and zanubrutinib PO BID cycles 1-13 days 1-28 during the study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and while on the study and may undergo tissue and/or bone marrow biopsy at screening, on study, and at time of progression.
PART II: Patients are randomized to 1 of 3 arms (Arms I, II or III).
ARM I: Patients receive tafasitamab IV on cycle 1 days 1, 4, 8, 15 and 22, cycles 2-3 days 1, 8, 15 and 22, cycles 4-13 days 1 and 15, lenalidomide PO QD cycles 1-13 days 1-21, and tazemetostat PO BID cycles 1-13 days 1-28 during the study. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and during the study and may undergo tissue and/or bone marrow biopsy at screening, on study, and at time of progression.
ARM II: Patients receive tafasitamab IV on cycle 1 days 1, 4, 8, 15 and 22, cycles 2-3 days 1, 8, 15 and 22, cycles 4-13 days 1 and 15 and lenalidomide PO QD cycles 1-13 days 1-21 on study. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and while on the study and may undergo tissue and/or bone marrow biopsy ay screening, on study, and at time of progression.
ARM III: Patients receive tafasitamab IV on cycle 1 days 1, 4, 8, 15 and 22, cycles 2-3 days 1, 8, 15 and 22, cycles 4-13 days 1 and 15, lenalidomide PO QD cycles 1-13 days 1-21, and zanubrutinib PO BID-QD cycles 1-13 days 1-28 during the study. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and while on the study and may undergo tissue and/or bone marrow biopsy at screening, on study, and at time of progression.
After completion of study treatment, patients are followed up every 3 months in the first year and every 6 months for years 2 and 3.
Trial PhasePhase II
Trial Typetreatment
Lead OrganizationSWOG
Principal InvestigatorJennifer Effie Amengual
- Primary IDS2207
- Secondary IDsNCI-2023-02518
- ClinicalTrials.gov IDNCT05890352